WaveMan
WaveMan · Company
IMMX · Immix Biopharma, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

IMMX Immix Biopharma (IMMX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001873835
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
81
13F, latest reported quarter

Immix Biopharma insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Immix Biopharma, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Rachman Ilya M
CEO and Chairman
BUY
2025-12-10 SEC
746
$5.0K
+9.2%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Sep 17, 2025.
  • +3.4% median (+40.9% mean) 90-day return after 7 previous buys.
  • The trade is 0.1% of the 1,141,683 shares held after it.
  • 1 other insider bought within 30 days.
  • 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and Chairman Rachman Ilya M bought about $5.0K of IMMX on Dec 10, 2025; 1 other insider bought within 30 days and 81 funds added in the latest 13F quarter.
Morris Gabriel S
CFO
BUY
2025-12-10 SEC
770
$5.1K
+9.2%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Sep 16, 2025.
  • +3.4% median (+41.9% mean) 90-day return after 7 previous buys.
  • The trade is 0.3% of the 291,429 shares held after it.
  • 1 other insider bought within 30 days.
  • 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO Morris Gabriel S bought about $5.1K of IMMX on Dec 10, 2025; 1 other insider bought within 30 days and 81 funds added in the latest 13F quarter.
Rachman Ilya M
CEO and Chairman
BUY
2025-09-17 SEC
2,500
$5.0K
+285.6%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Jun 18, 2025.
  • -6.2% median (+13.9% mean) 90-day return after 6 previous buys.
  • The trade is 0.2% of the 1,140,937 shares held after it.
  • 1 other insider bought within 30 days.
  • 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and Chairman Rachman Ilya M bought about $5.0K of IMMX on Sep 17, 2025; 1 other insider bought within 30 days and 81 funds added in the latest 13F quarter.
Morris Gabriel S
CFO
BUY
2025-09-17 SECtraded 2025-09-16
2,600
$5.1K
+285.6%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Jun 18, 2025.
  • -6.2% median (+13.9% mean) 90-day return after 6 previous buys.
  • The trade is 0.9% of the 290,659 shares held after it.
  • 1 other insider bought within 30 days.
  • 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO Morris Gabriel S bought about $5.1K of IMMX on Sep 16, 2025; 1 other insider bought within 30 days and 81 funds added in the latest 13F quarter.
Rachman Ilya M
CEO and Chairman
BUY
2025-06-20 SECtraded 2025-06-18
2,178
$5.0K
+261.4%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Jun 7, 2024.
  • +3.4% median (+19.9% mean) 90-day return after 5 previous buys.
  • The trade is 0.2% of the 1,138,437 shares held after it.
  • 1 other insider bought within 30 days.
  • 81 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and Chairman Rachman Ilya M bought about $5.0K of IMMX on Jun 18, 2025; 1 other insider bought within 30 days and 81 funds added in the latest 13F quarter.
43 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 38 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
81 funds bought in last quarter
more than 60% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
18.4% of the float short (float per yahoo 2026-10-27) · 7.5 days to cover · settled 2026-10-15
more than 85% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch IMMX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+135.0%12M
-12%+100%+211%+322%2025-102025-122026-022026-042026-062026-082026-10 2025-12-10 · Morris Gabriel S bought $5.1K2025-12-10 · Rachman Ilya M bought $5.0K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns IMMX: institutional holders (13F)

13F holdings, latest reported quarter
Jupiter Topco LLC
9,783,192 sh
$100.8M
Saturn V Capital Management LP
4,658,429 sh
$48.0M
EVENTIDE ASSET MANAGEMENT, LLC
3,891,019 sh
$40.1M
STATE STREET CORP
2,996,935 sh
$30.9M
BlackRock, Inc.
2,989,972 sh
$30.8M

Congress trades in IMMX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

IMMX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

IMMX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Timber Point Global Allocations Fund
$1.4M position · as of 2026-06-30
4.5%
Eventide Healthcare & Life Sciences Fund
$40.1M position · as of 2026-06-30
2.2%
Ultra-Small Company Fund
$824.8K position · as of 2026-06-30
0.8%
Virtus Biotech Clinical Trials Etf
$306.0K position · as of 2026-07-31
0.7%
Franklin Biotechnology Discovery Fund
$3.0M position · as of 2026-07-31
0.3%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$21.7M position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 81 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

IMMX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$39.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-34.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-31.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-35.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-6.8%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$30.0M-$22.7M-$16.1M-$8.2M
Net income-$29.4M-$21.6M-$15.4M-$8.2M
EPS (diluted)-0.89-0.76-0.89-0.59
Operating cash flow-$23.9M-$14.6M-$11.4M-$7.4M
Cash$93.9M$17.7M$17.5M$13.4M
Buybacksn/an/an/a$100.0K
SEC XBRL, fiscal years, as known on 2026-10-28

IMMX Stock Sonar score 3/7 axes

Find similar shapesCompare

IMMX ranks highest on profitability (63rd percentile) and institutional and government (53rd), and lowest on risk and compliance (19th), among Pharma & Biotech peers.

Profitability
63
Inputs
  • Return on equity-34.1% · 64 pct, sector of 545
  • Return on assets-31.3% · 59 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-35.5% · 65 pct, sector of 576
Institutional and government
53
Inputs
  • Funds adding, latest quarter81 · 60 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$215K · 46 pct, sector of 133
Risk and compliance
19
Inputs
  • Short interest, % of float+17.8% · 19 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Financial health, Growth, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies